Posted by Michael Wonder on 05 Apr 2018
Specialised Therapeutics initiates early access program for neratinib maleate
5 April 2018 - Specialised Therapeutics today announces the initiation of an early access program for neratinib maleate an extended adjuvant treatment for early-stage HER2-positive breast cancer.
Under this Special Access Program (SAP) select patients in Australia will be provided access to the medicine, where appropriate and when permitted by relevant regulatory authorities.
The SAP protocol allows for neratinib maleate to be available to patients with HER2 over-expressing cancers.
